Skip to main content
. Author manuscript; available in PMC: 2016 Jul 1.
Published in final edited form as: Apoptosis. 2015 Jul;20(7):996–1015. doi: 10.1007/s10495-015-1131-3

Fig. 1. Human neural stem cells (NSC) and human melanoma cell lines used in this study.

Fig. 1

(A) NSC, eight human melanoma cell lines and glioblastoma U87MG were used. BRAF status is indicated: BRAF wild-type (wt) protein in human NSC, FEMX metastatic (MET) melanoma and U87MG glioblastoma; BRA V600E mutated variant in WM35 radial growth phase (RGP) melanoma cells, WM793 vertical growth phase (VGP), WM9, 1235Lu, HHMSX and A375 metastatic (MET) melanoma cells and OM431 ocular melanomas. PTEN status: Wild type (wt), Deleted (Del), Hemi-deleted (Hem Del), Mutated (Mu). (B) Immunostaining and surface expression of indicated receptor in NSC that was determined by FACS analysis; % positive cells is indicated, ns means non-specific staining. (C) Confocal analysis of images after immunostaining using rabbit polyclonal Ab to SOX2, a pluriopotency marker (green) and monoclonal antibody to Nestin , an early neuroprogenitor marker (red). Bar = 50 μm. (D) Percentage of Nestin-positive cells among melanoma and glioblastoma lines. Error bars represent mean ± SD (p < 0.05, Student’s t test). Stars indicate significant difference.